Computational Biology News
-
CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI
CD ComputaBio, a reputable computational service provider in the field of biology, has proudly announced the launch of its Antibody De Novo Design technology, marking a pivotal moment in the field of drug discovery and development. This service harnesses the power of AI to engineer antibodies with unmatched precision, paving the way for targeted therapies, personalized medicine, and cutting-edge ...
-
CD ComputaBio Unveils Cutting-Edge Advances in Antibody Drug Design and Development
Prominent within the field of computational biology, CD ComputaBio, unveils its cutting-edge Antibody Drug Design Services and Antibody Development solutions. Driven by an unwavering commitment to advancing precision medicine, the company stands at the forefront of redefining therapeutic strategies and expediting drug discovery processes, fostering innovation within the healthcare industry. In ...
-
CD Computabio Unleashes the Power of Computational Biology with Innovative Virtual Screening Service
CD Computabio, a prominent provider of computational biology solutions, is excited to introduce its virtual screening service based on pharmacophore fragments. This approach is poised to revolutionize the field of drug discovery by offering researchers an efficient and cost-effective solution for identifying promising drug candidates. In the early stages of drug development, virtual screening ...
-
Accelerating Drug Development with CD ComputaBio's Advanced Drug Design and CADD Solutions
CD ComputaBio, a reputable computational service provider in the field of biology, is dedicated to supporting research and trials by offering access to the latest software, technologies, and expertise at competitive prices and with fast turnaround times for researchers. Recently, the company introduced a series of state-of-the-art services in Drug Design and Computer-Aided Drug Design (CADD) with ...
-
CD ComputaBio Boosts Small Molecule Drug Development with Protein-Small Molecule Docking Service
CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise at competitive prices and with fast turnarounds for researchers. The company is pleased to announce the launch of the Protein-Small Molecule Docking service, designed to help customers quickly ...
-
CD ComputaBio Introduces AutoDock, a Powerful Molecular Docking Software
CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise at competitive prices and with fast turnarounds for researchers. The company is ready to support your molecular docking projects with its innovative AutoDock software. Autodock is an ...
-
First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Cancer Patients
Biolojic uses its proprietary AI platform to design antibodies with new capabilities to cure disease, ushering in a new era of smart therapeutics Biolojic Tel Aviv to focus on computational design of antibodies; Boston location will focus on drug development Biolojic Design, a unique technology company pioneering computational design of human antibodies to develop smart therapeutic ...
-
Why Knowledge Is Power In The Treatment Of Obesity
Dr. Ali Tinazli is the CEO of lifespin.health and has 15+ years in Fortune 100 corporate strategy and entrepreneurship (SONY, HP). Obesity rates continue to climb alongside a $254.9 billion global weight loss products and services market. Supplements, smartphone weight loss apps, diet plans and exercise programs are widely available to consumers, yet the World Obesity Federation projects that 1 ...
-
Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets
Cellworks Group Inc., a leader in Personalized Therapy Biosimulation, today announced the launch of its Precision Drug Development business units aimed at accelerating time-to-market for drug development and reviving previously studied but unapproved pharmaceutical assets through predictive biosimulation. The two new business units will use Cellworks’ biosimulation platform and ...
-
iBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery Engine
BRYAN, Texas, Jan. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,545,238, entitled “Machine Learning Method For Protein Modelling To Design Engineered Peptides,” which ...
By Ibio, Inc.
-
CD ComputaBio Releases AutoDock Vina Software to Accelerate Molecular Docking Projects
CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise with competitive prices and fast turnarounds for researchers. The company has recently announced the introduction of its Autodock Vina software, designed to predict the mechanism of small ...
-
ASH 2022: Cellworks Biosimulation Study Reveals Biomarkers that Predict Response to Hypomethylating Agents and Patient Survival in MDS
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a study that examined how Differentiation Scoring (DS) derived from key myeloid biomarkers in individual Myelodysplastic Syndrome (MDS) patients using the Cellworks Platform and Computational Biology Model (CBM) can predict response to Hypomethylating Agents (HMA). In ...
-
iBio Announces Closing of $3.5 Million Underwritten Public Offering
BRYAN, Texas, Dec. 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its previously announced underwritten public offering of an aggregate of 3,365,385 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase ...
By Ibio, Inc.
-
iBio Announces Pricing of $3.5 Million Underwritten Public Offering
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its previously announced underwritten public offering of an aggregate of 3,365,385 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase ...
By Ibio, Inc.
-
iBio Announces Proposed Underwritten Public Offering
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced it intends to offer and sell, subject to market and other conditions, shares of its common stock (or common stock equivalents in lieu thereof) and Series A and Series B warrants to purchase shares ...
By Ibio, Inc.
-
CD ComputaBio Introduces PyMOL Software for Bioinformatics Analysis
CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise with competitive prices and fast turnarounds for researchers. The company has announced the introduction of the PyMOL software, a powerful utility for studying proteins, DNA, and other ...
-
Cellworks Therapy Biosimulation Study Reveals Promising New Biomarkers for TMZ Resistance in Glioblastoma Patients
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a Cellworks biosimulation pilot study, which examined the impact of mismatch repair deficiency (MRD) on survival of temozolomide (TMZ)-treated patients with MGMT methylated (m-MGMT) glioblastoma (GBM). The biosimulation study validated that TMZ does not trigger ...
-
OpenFold AI Research Consortium Welcomes 4 New Members: Bayer, Dassault, CHARM Therapeutics and BaseCamp Research
OpenFold, a non-profit artificial intelligence (AI) research consortium whose goal is to develop free and open source software tools for biology and drug discovery, today announced the addition of four new industry members: Bayer, Dassault Systèmes, CHARM Therapeutics, and BaseCamp Research Ltd. OpenFold, a consortium of academic and industry partners founded in February 2022, is a ...
-
CD ComputaBio Introduces Four Docking Software for Drug Development
CD ComputaBio, a reliable computational service provider in the field of biology, is committed to assisting research and trials, as well as accessing the latest software, technologies, and expertise at a competitive price and fast turnaround for researchers. Molecular docking is a popular technique in drug design for predicting both binding patterns and binding affinity. CD ComputaBio has ...
-
iBio Accelerates Transformation to AI-Powered Biotech
BRYAN, Texas and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) an AI-driven innovator of precision antibody immunotherapies, announces it is seeking to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an antibody discovery and development company. ...
By Ibio, Inc.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you